Patents by Inventor Jeffrey L. Larson

Jeffrey L. Larson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA sequences encoding porcine pancreatic carboxypeptidase B
    Patent number: 5672496
    Abstract: DNA encoding porcine Pro-carboxypeptidase B, vectors comprising the DNA and host cells transformed with the vectors are useful for production of porcine carboxypeptidase B
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: September 30, 1997
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey T. Fayerman, David P. Greenen, Charles L. Hershberger, Jeffrey L. Larson, Jane L. Sterner, Haichao Zhang
  • Plasmid pHKY334, an expression vector for EK-BGH and host cells transformed therewith
    Patent number: 5395761
    Abstract: Plasmid pHKY334, an expression vector for Met-Phe-Pro-Leu-(Asp).sub.4 -Leu-BGH, and host cells containing plasmid pHKY334 are disclosed and claimed.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: March 7, 1995
    Assignee: Eli Lilly and Company
    Inventors: Charles L. Hershberger, Jeffrey L. Larson
  • Ultrahigh copy number streptomycetes plasmids
    Patent number: 4898828
    Abstract: The present invention discloses an .about.1.4 kb Bc1I-Sau3A restriction fragment containing the minimal replicon of the Streptomyces coelicolor plasmid SCP2*. This minimal replicon was deduced from plasmid derivatives constructed by in vitro deletions and has been identified as the smallest, self-replicating segment of the SCP2* plasmid. The minimal replicon specifies an ultrahigh level of plasmid DNA (more than 1000 fold increase from the basic replicon) when vectors containing this sequence are transformed into Streptomyces lividans. This replicon can be used to construct smaller, more efficient recombinant DNA shuttle vectors to clone DNA into streptomycetes.
    Type: Grant
    Filed: March 20, 1986
    Date of Patent: February 6, 1990
    Assignee: Eli Lilly and Company
    Inventors: Charles L. Hershberger, Jeffrey L. Larson, Patricia A. Reynolds
  • Plasmid PHJL210 and related bifunctional cloning vectors for use in streptomycetes
    Patent number: 4753886
    Abstract: The present invention discloses selectable, recombinant DNA shuttle vectors for use in streptomycetes and E. coli. The shuttle vectors of the present invention are present at moderately high copy number. The invention further discloses transformants of the aforementioned vectors.
    Type: Grant
    Filed: August 10, 1984
    Date of Patent: June 28, 1988
    Assignee: Eli Lilly and Company
    Inventors: Charles L. Hershberger, Jeffrey L. Larson
  • Chimeric cloning vectors for use in streptomyces and E. Coli
    Patent number: 4752574
    Abstract: The present invention discloses chimeric plasmid SCP2 and SCP2* cloning vectors that are useful in Streptomyces and E. coli. The invention further discloses transformants and a method for detecting transformants of the aforementioned vectors.
    Type: Grant
    Filed: April 30, 1987
    Date of Patent: June 21, 1988
    Assignee: Eli Lilly and Company
    Inventors: Charles L. Hershberger, Jeffrey L. Larson
  • Method of cloning modified streptomycetes DNA
    Patent number: 4710466
    Abstract: A method of cloning endogenously modified Streptomycetes DNA, which is normally rejected by restrictionless heterospecific hosts, is disclosed. The method uses bacteriophage lambda to construct a genomic library of modified Streptomycetes DNA; such lambda-containing Streptomycetes DNA is replicated to provide a source of non-modified Streptomycetes DNA. This non-modified DNA is subcloned into a selectable cloning vector and used to transform restrictionless hetero-specific hosts. The transformants can then be screened for clones containing genes of interest.
    Type: Grant
    Filed: September 25, 1984
    Date of Patent: December 1, 1987
    Assignee: Eli Lilly and Company
    Inventors: Charles L. Hershberger, Jeffrey L. Larson